Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Third-Quarter Performance by Business

This excerpt taken from the EYE 8-K filed Oct 31, 2008.

Third-Quarter Performance by Business

Below are sales highlights of third-quarter 2008 results. Growth rates reflect comparisons to the same period in 2007 and include foreign currency impacts. Pro forma growth rates reflect comparisons that include IntraLase performance as if this acquisition had occurred at the beginning of all periods presented. The summary below also reflects changes made at the beginning of 2008 to the company’s sales breakdown by business. Under this new approach, refractive IOL sales for the third quarter of 2008 and 2007 appear under the Refractive heading in the “Procedures, implants and related” category to reflect the way the company currently operates. For more information, see the Global Sales table accompanying this release.

This excerpt taken from the EYE 8-K filed Aug 4, 2008.

Second-Quarter Performance by Business

Below are sales highlights of second-quarter 2008 results. Growth rates reflect comparisons to the same period in 2007 and include foreign currency impacts. Pro forma growth rates reflect comparisons that include IntraLase performance as if this acquisition had occurred at the beginning of all periods presented. The summary below also reflects changes made at the beginning of 2008 to the company’s sales breakdown by business. Under this new approach, refractive IOL sales for the second quarter of 2008 and 2007 appear under the Refractive heading in the “Procedures, implants and related” category to reflect the way the company currently operates. For more information, see the Global Sales table accompanying this release.

This excerpt taken from the EYE 8-K filed May 1, 2008.

First-Quarter Performance by Business

Below are sales highlights of first-quarter 2008 results. Growth rates reflect comparisons to the same period in 2007 and include foreign currency impacts. Pro forma growth rates reflect comparisons that include IntraLase performance as if this acquisition had occurred at the beginning of all periods presented. The summary below also reflects changes made to the company’s sales breakdown by business. Under this new breakdown, refractive IOL sales for the first quarter of 2008 and 2007 appear under the Refractive heading in the “Procedures, implants and related” category to reflect the way the company currently runs its business. For more information, see the Global Sales table accompanying this release.

This excerpt taken from the EYE 8-K filed Oct 25, 2007.

Third-Quarter Performance by Business

Below are sales highlights of third-quarter 2007 results by business. Growth rates reflect comparisons to the same period in 2006 and include the impacts of foreign currency. Pro forma growth rates reflect comparisons that include IntraLase and WaveFront Sciences performance in the same period of 2006. For more information, see the table entitled “Global Sales” that accompanies this release.

Cataract/Implant sales rose 5.2 percent to $131.7 million.

 

  •  

Total intraocular lens (IOL) sales rose 6.5 percent to $74.3 million.

 

 

•

  

Monofocal IOL sales rose 7.6 percent to $61.4 million, reflecting continued strong growth of the Tecnis® IOL franchise.

 

  •  

Refractive IOL sales grew 1.2 percent to $12.8 million, reflecting continued demand in international markets, while domestic sales slowed.

 

 

•

  

Sales of AMO’s Healon® family of viscoelastics declined 1.0 percent. Total viscoelastics sales of $30.1 million declined 2.2 percent, due primarily to the lack of a dispersive viscoelastic in the U.S. and continued pricing pressure in certain international markets.

 

 

•

  

Phacoemulsification sales increased 11.4 percent to $22.4 million. Surgical pack sales rose 12.8 percent and systems sales increased 11.4 percent, driven by strong growth from the company’s established phacoemulsification franchise and the recently launched WhiteStar SignatureTM system.

Laser Vision Correction (LVC) sales rose 95.4 percent to $99.3 million, or 15.8 percent on a pro forma basis.

 

  •  

Procedures and related sales of $62.9 million represented a 90.3 percent increase, or 30.5 percent on a pro forma basis.

 

  •  

AMO’s U.S. excimer procedure volumes grew 8.6 percent and its U.S. custom procedure mix reached 63.8 percent for the trailing 12 months ended September 28.

 

  •  

AMO’s U.S. femtosecond procedure volumes grew 35.8 percent for the trailing 12 months ended September 28 on a pro forma basis.

 

  •  

International procedure sales were $18.8 million, which included excimer procedure sales of $6.5 million, up 74.9 percent, and femtosecond procedure sales of $12.3 million, up 81.5 percent on a pro forma basis.

 

 

•

  

System sales increased 175.4 percent to $27.3 million, or an increase of 2.3 percent on a pro forma basis. On a unit basis, placements of the VISX Star S4 IR® excimer laser rose 2.7 percent; IntraLase® FS laser placements rose 36.7 percent on a pro forma basis.

Eye Care sales declined 48.9 percent to $42.2 million.

 

 

•

  

Multipurpose sales declined 73 percent to $13.0 million, which included approximately $6.3 million in returns and an estimated $32.3 million in lost sales related to the recall, partially offset by the re-launch of Complete® Easy RubTM Multipurpose Solution in the U.S. and Europe.

 

2

• Hydrogen peroxide sales declined 10.3 percent to $16.4 million.

EXCERPTS ON THIS PAGE:

8-K
Oct 31, 2008
8-K
Aug 4, 2008
8-K
May 1, 2008
8-K
Oct 25, 2007

RELATED TOPICS for EYE:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki